(lp0
S'Alimera Sciences: 2017 Outlook Seeking Alpha - Feb 10, 2017 Alimera had a big sequential jump in net sales in Q2 followed by a dip in Q3. The company explained on the Q3 call that Q2 sales were inflated by a distributor inventory buildup and that end-user demand was actually slightly higher in Q3 compared to Q2.'
p1
aS'Numbers in Review on Shares of Alimera Sciences Inc  Rives Journal - 15 hours ago Narrowing in on moving averages for Alimera Sciences Inc , the 200-day is at 1.35, the 50-day is 1.36, and the 7-day is resting at 1.42.'
p2
aS'Alimera Sciences Inc  Upgraded at Zacks Investment Research The Cerbat Gem - Apr 17, 2017 Alimera Sciences logo Alimera Sciences Inc  was upgraded by Zacks Investment Research from a sell rating to a hold rating in a report issued on Friday.An End-of-Day Technical Review: MoSys, Inc. , Alimera Sciences, Inc.  - Post Analyst'
p3
aS"Alimera Sciences, Inc.  Looks Good: Stock Up 12.8% Yahoo Finance - Mar 14, 2017 Alimera Sciences, Inc. ALIM was a big mover last session, as the company saw its shares rise almost 13% on the day. The upside was driven by the company's improved fourth-quarter and full-year 2016 results."
p4
aS'Company Focus: Zooming in on Shares of Alimera Sciences, Inc.  Benton Bulletin - 9 hours ago Interested investors may be tracking the Piotroski F-Score. Alimera Sciences, Inc.  currently has a Piotroski F-Score of 4. The aim of the F-Score is to help discover companies with strengthening balance sheets, and to eliminate the poor&nbsp;...'
p5
aS'Eye drug company Alimera Sciences mulls sale: sources Reuters - Dec 17, 2015 Alimera Sciences Inc, an ophthalmic pharmaceutical company, is in the early stages of exploring strategic alternatives, including a potential sale, according to people familiar with the matter.Alimera Sciences Inc  Stock is Up Amid Reaching Distribution Drug Deal ... - Independent Reporter'
p6
aS"Alimera: Risks Reduced After Q2 Pre-Announcement Seeking Alpha - Jul 28, 2016 The company's market cap before today's jump was just around $50 million, which is very low considering Iluvien's potential."
p7
aS'Under the Lens: Stock Review for Alimera Sciences, Inc.  BVN - 9 hours ago Looking at shares of Alimera Sciences, Inc. , the company presently has a Gross Margin  ratio of 0.455496.'
p8
aS"Here's Why Cowen Upgraded Alimera Sciences Inc  Shares Smarter Analyst - Sep 16, 2016 With near-term financing overhang removed and more confident in Iluvien's sales growth, Cowen analyst Boris Peaker upgrades shares of Alimera Sciences Inc  from Market Perform to Outperform, while issuing a $3 price target, which&nbsp;...UPDATE: Cowen Sees Opportunity in Alimera Sciences  and Upgrades Stock ... - StreetInsider.com"
p9
aS"Alimera Sciences, Inc. and VIVUS Inc. Head to Head Compare CML News - Apr 15, 2017 Alimera Sciences Inc has a higher fundamental rating than VIVUS Inc which has an impact on the head-to-head comparison. The CML Star Rating is an objective, quantifiable measure of a company's operating and financial condition."
p10
a.